Soleno Therapeutics, Inc.

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of rare diseases, particularly Prader-Willi syndrome (PWS). Their lead product candidate, DCCR (Diazoxide Choline) Extended-Release tablets, is a once-daily oral tablet being developed for PWS and other rare endocrine disorders. DCCR has received Orphan Drug Designation for the treatment of PWS in the United States and Europe, and its development has been designated a Fast Track development program by the FDA. Soleno is committed to improving the lives of patients with rare diseases and their families by providing safe and effective treatment options.

Soleno Therapeutics is headquartered in Redwood City, California, and has a team of experienced professionals in drug development, clinical research, regulatory affairs, and commercialization. The company is actively engaged in clinical trials to evaluate the safety and efficacy of DCCR for the treatment of PWS and other rare genetic disorders. Soleno is committed to building a sustainable business that delivers value to shareholders while making a positive impact on the lives of patients and their families.

Soleno Therapeutics does not explicitly state their policy on job flexibility. However, one of the open positions listed on their careers page, Director of Sales Training, requires up to 30% travel, suggesting a potential need for on-site presence and limited remote work options.

Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat rare diseases, particularly Prader-Willi syndrome (PWS). They are driven by the needs of patients and families impacted by these disorders, striving to create safe and effective treatment options that improve quality of life and address unmet medical needs. Soleno is committed to delivering meaningful outcomes for patients and their families, emphasizing collaboration, integrity, and respect in all aspects of their work.

Soleno Therapeutics promotes a collaborative, respectful, and results-oriented culture. They value integrity and encourage their employees to be accountable for their actions. The company prioritizes innovation and embraces change, while fostering a sense of resilience to overcome challenges. Their focus on developing safe and effective treatments for rare diseases like Prader-Willi Syndrome motivates their team to work hard and make a difference in the lives of patients and families.

Soleno Therapeutics, Inc. is committed to fostering a diverse workforce by making employment decisions without discrimination based on race, color, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information, gender identity and expression, veteran status, or other non-job related characteristics. They actively promote a culture of collaboration, integrity, and respect to ensure everyone feels valued and included.